Impetigo Therapeutic Market - Forecast(2024 - 2030)

Report Code: HCR 0942 Report Format: PDF + Excel

Impetigo Therapeutic Market Overview

Impetigo Therapeutic Market size is estimated to reach $877.3 million by 2027, growing at a CAGR of 7.2% during the forecast period 2022-2027. Impetigo is a typical and greatly contagious skin infection that principally influences babies and young children. It normally materializes as reddish sores on the face, specifically around the nose and mouth and on the hands and feet. Over around a week, the sores burst and establish honey-colored crusts. Impetigo Therapeutic involves impetigo being treated with prescription mupirocin antibiotic ointment or cream used directly on the sores two to three times a day for five to 10 days. A typical Impetigo Therapeutic Industry application includes the development of novel medicines limiting the reoccurrence of the ailment and enhancing the cosmetic appearance of the marks. Impetigo is a superficial skin infection with crusting or bullae brought about by streptococci, staphylococci or both. The forecast of treatment success for impetigo is reliant on the presence or absence of scabies and for scabies coinfected impetigo it was greater in the group treated with co-trimoxazole (SXT). Oral antibiotic therapy may be utilized for impetigo with big bullae or when topical therapy is unrealistic. Amoxicillin/clavulanate, dicloxacillin, cephalexin, clindamycin, doxycycline, minocycline, trimethoprim/sulfamethoxazole and macrolides are alternatives, however, penicillin is not. Nonbullous impetigo is usually treated with antibiotics. The soaring awareness regarding impetigo involving the application of prescription mupirocin antibiotic ointment or cream and the reduced cost of treatment is set to drive the Impetigo Therapeutic Market. The burgeoning crowded conditions like schools and daycare are set to propel the growth of the Impetigo Therapeutic Industry during the forecast period 2022-2027. This represents the Impetigo Therapeutic Industry Outlook.

Impetigo Therapeutic Market Report Coverage

The Impetigo Therapeutic Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Impetigo Therapeutic Market.

By Treatment Option: Antibiotics and Others.
By Route Of Administration: Oral, Topical and Others.
By End-use Industry: Hospitals, Specialty Clinics, Home Healthcare and Others.
By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and Others.
By Geography: North America (the U.S., Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America) and Rest Of The World (the Middle East and Africa).

Key Takeaways

  • Geographically, North America (Impetigo Therapeutic market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of impetigo which can be bullous or nonbullous during the summer in the U.S. in the North American region.
  • Impetigo Therapeutic Market growth is being driven by the rising pervasiveness of impetigo and ecthyma together with the surging population of babies and adolescents. However, the hazard of side effects brought about by numerous medications and drug therapies at the time of the treatment of impetigo is one of the major factors hampering the growth of the Impetigo Therapeutic Market.
  • Impetigo Therapeutic Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Impetigo Therapeutic Market report.

Impetigo Therapeutic Market: Market Share (%) by Region, 2021

Impetigo Therapeutic Market

For More Details On this report - Request For Sample

Impetigo Therapeutic Market Segment Analysis - By Treatment Option

The Impetigo Therapeutic Market based on treatment options can be further segmented into Antibiotics, Others. The Antibiotics Segment held the largest Impetigo Therapeutic market share in 2021. This growth is owing to the surging application of antibiotics for the treatment of Impetigo. Mupirocin and clindamycin can be utilized for the treatment of Impetigo. The soaring application of topical antibiotics, systemic antibiotics and topical disinfectants for treating impetigo are further propelling the growth of the Antibiotics segment.

Furthermore, the Antibiotics segment is estimated to grow with the fastest CAGR of 8.3% during the forecast period 2022-2027 owing to the heightening suggestion of Mupirocin 2 percent cream or ointment (Bactroban), retapamulin 1 percent ointment (Altabax) and fusidic acid as three topical antibiotic preparations for impetigo and the extensive preference for cost-effective and efficient medicines with lesser side-effects.

Impetigo Therapeutic Market Segment Analysis - By End-use Industry

The Impetigo Therapeutic Market based on the end-use industry can be further segmented into Hospitals, Specialty Clinics, Home Healthcare and Others. The Hospitals Segment held the largest Impetigo Therapeutic market share in 2021. This growth is owing to the increasing inclination of patients toward hospitals for the diagnosis of Impetigo. Impetigo may be bullous or non-bullous. Toxin-producing S. aureus brings about bullous impetigo. S. aureus, S. pyogenes or both bring about non-bullous impetigo, which is also termed “impetigo contagiosa.” The presence of advanced infrastructure and the effortless availability of qualified and skilled physicians and multidisciplinary teams in hospitals is further propelling the growth of this segment.

Furthermore, the Home Healthcare segment is estimated to grow with the fastest CAGR of 8.5% during the forecast period 2022-2027 owing to the extensive application of over-the-counter antibiotic cream or ointment for treating the sores in the case of minor infections that have not spread to additional areas.

Impetigo Therapeutic Market Segment Analysis - By Geography

The Impetigo Therapeutic Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Impetigo Therapeutic Market) held the largest Impetigo Therapeutic market share with 35% of the overall market in 2021. The growth of this region is owing to the enormous count of cases of impetigo infection requiring medications like mupirocin and clindamycin in the U.S. in the North American region. The existence of key players like MedimetriksPharmaceuticals, Inc. in the U.S. in North America is further propelling the growth of the Impetigo Therapeutic Industry, thereby contributing to the Impetigo Therapeutic Industry Outlook, in the North American region.

Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the burgeoning healthcare infrastructure and surging awareness of skin infections in the Asia-Pacific region. The increasing predominance of impetigo infections in hot and humid areas and also cases of scabies are further fuelling the progress of the Impetigo Therapeutic Market in the Asia-Pacific region.

Impetigo Therapeutic Market Drivers

Significance of Ecthyma is Projected to Drive the Growth of Impetigo Therapeutic Market:

Ecthyma is an augmented pyoderma than impetigo and is much less typical. It has an inclination for the extremities of children, frequently at sites of minor trauma, which permit entry of the causative bacteria. Group A streptococci, specifically S. pyogenes, are normally under suspicion, though coagulase-positive staphylococci are at times isolated as well. Ecthyma gangrenosum is a serious variation of ecthyma observed in 5% or greater of immunosuppressed individuals who develop septicemia with Pseudomonas aeruginosa. Ecthyma appears like nonbullous impetigo in onslaught and appearance however gently evolves into a deeper, more incessant infection. Ecthyma is an ulcerative kind of impetigo characterized by erosions into the dermis. Formerly, nonbullous impetigo could be confidently diagnosed as streptococcal and distinguished from bullous impetigo brought about by Staphylococcus aureus. More currently, however, S. aureus has been isolated with a heightening frequency from nonbullous impetigo in the setting of penicillin treatment failure. The significance of Ecthyma is therefore fuelling the growth of the Impetigo Therapeutic Market during the forecast period 2022-2027.

Surging Applications of Mupirocin and Clindamycin for Impetigo are Expected to Boost the Growth of the Impetigo Therapeutic Industry:

The antimicrobial range for mupirocin involves staphylococci (MRSA, MSSA), streptococci, anaerobes and Enterobacteriaceae. The principal application of mupirocin is as a topical application for skin infections, like impetigo owing to S. aureus or S. pyogenes. Mupirocin is also utilized to decrease or remove nasal carriage of staphylococci, specifically MRSA. Its extensive application is related to a boost in the reinfection rate owing to resistance development or reinfection from additional body areas. Numerous investigations recommend that extensive application of prophylactic mupirocin may lead to raised levels of resistance. In Canada surging application of mupirocin across the nation resulted in high-level mupirocin resistance, increasing from 1.6% to 7% over a 9-year period. Clindamycin may be utilized for the treatment of impetigo. The surging applications of Mupirocin and Clindamycin for Impetigo are therefore driving the growth of the Impetigo Therapeutic Industry, thereby contributing to the Impetigo Therapeutic Industry Outlook during the forecast period 2022-2027.

Impetigo Therapeutic Market Challenge

Complexities from Impetigo are Hampering the Growth of the Impetigo Therapeutic Market:

Impetigo is responsible for nearly 10% of skin complaints in the pediatric populace. The bacteria bringing about impetigo can become invasive, resulting in cellulitis and lymphangitis. Consequently, bacteremia may lead to osteomyelitis, septic arthritis or pneumonia. In babies under six years of age or mature grown-ups with renal insufficiency, localized bullous impetigo owing to particular staphylococcal serotypes can result in a sick child with generalized staphylococcal scalded skin syndrome (SSSS). Superficial crusting then tenders cutaneous denudation on the face, in flexures and elsewhere is owing to circulating exfoliatin/epidermolysis, instead of a direct skin infection. These issues are thus hampering the growth of the Impetigo Therapeutic Market.

Impetigo Therapeutic Industry Outlook

Novel product launches, clinical trial pipelines, product approvals, patents, partnerships and potential financing in R&D are key strategies adopted by players in the Impetigo Therapeutic Market. The top 10 companies in the Impetigo Therapeutic market are:

  1. Foamix Pharmaceuticals Ltd.
  2. Laboratories Ojer Pharma S.L.
  3. NovaBay Pharmaceuticals Inc.
  4. Lytix Biopharma AS
  5. Toyama Chemical Co. Ltd.
  6. Medimetriks Pharmaceuticals, Inc.
  7. Teva Pharmaceuticals Industries Ltd
  8. Novartis AG
  9. Hikma Pharmaceuticals PLC
  10. Aurobindo Pharma

Recent Developments

  • In November 2021, the formerly declared acquisition of DERMAdoctor, LLC by NovaBay® Pharmaceuticals, Inc. was finished. The firm also established that it will discharge financial outcomes for the third quarter of 2021 on Thursday, November 11, 2021, and will host an investor conference call at 4:30 p.m. Eastern time on that day. In the acquisition of DERMAdoctor, the firm was counseled by Two Roads Advisors LLC, a boutique investment bank guided by John Z. Fang and Rob Cooper.
  • In March 2020, Menlo Therapeutics Inc. declared presently the completion of its merger with Foamix Pharmaceuticals Ltd. succeeding in the satisfaction of all closing conditions needed by the merger agreement. Upon the finish of the merger, agreeable to the terms of the merger agreement, Foamix became a wholly owned subsidiary of Menlo. Under the terms of the merger, Foamix shareholders accepted 0.5924 of a share of Menlo common stock for every Foamix share owned and a non-transferrable conditional stock right.
  • In January 2020, Novartis successfully finished the acquisition of The Medicines Company, including a promising first-in-class, investigational cholesterol-lowering therapy inclisiran. Above 50 million secondary prevention patients globally with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on the current standard of care do not accomplish LDL cholesterol (LDL-C) goal and stay at the raised hazard of cardiovascular events, The Medicines Company introduced the New Drug Application (NDA) for inclisiran to the FDA in December 2019, This concludes the Impetigo Therapeutic Industry Outlook.

Relevant Reports:

1. Impetigo Therapeutic Market Overview
    1.1 Definitions and Scope
2. Impetigo Therapeutic Market - Executive Summary
3. Impetigo Therapeutic Market – Market Landscape
    3.1 Company Benchmarking - Key Companies
    3.2 Key Company Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis (Comparison of General Price Offerings in the Market)
4. Impetigo Therapeutic Market – Startup Company Scenario (Premium)
    4.1 Investment
    4.2 Revenue
    4.3 Venture Capital and Funding Scenario
5. Impetigo Therapeutic Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Scenario
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Impetigo Therapeutic Market - Market Forces
    6.1 Market Drivers
    6.2 Market Constraints
    6.3 Porter's five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Impetigo Therapeutic Market – Strategic Analysis
    7.1 Value Chain Analysis 
    7.2 Opportunities Analysis
    7.3 Market Life Cycle Analysis
8. Impetigo Therapeutic Market – by Treatment Option (Market Size – $Million/$Billion) 
    8.1 Antibiotics
    8.2 Others
9. Impetigo Therapeutic Market – by Route Of Administration (Market Size – $Million/$Billion) 
    9.1 Oral
    9.2 Topical
    9.3 Others
10. Impetigo Therapeutic Market – by End-use Industry (Market Size – $Million/$Billion) 
    10.1 Hospitals
    10.2 Specialty Clinics
    10.3 Home Healthcare
    10.4 Others
11. Impetigo Therapeutic Market – by Distribution Channel (Market Size – $Million/$Billion) 
    11.1 Hospital Pharmacies
    11.2 Retail Pharmacies
    11.3 Online Pharmacies
    11.4 Others
12. Impetigo Therapeutic Market - by Geography (Market Size - $Million/Billion)
    12.1 North America
        12.1.1 the U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 Germany
        12.2.2 France
        12.2.3 the UK
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 Japan
        12.3.3 South Korea
        12.3.4 India
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest Of The World
        12.5.1 the Middle East
        12.5.2 Africa
13. Impetigo Therapeutic Market - Market Entropy
    13.1 New product launches
    13.2 M&A's, collaborations, JVs and partnerships
14. Impetigo Therapeutic Market – Industry Competition Landscape (Premium)
    14.1 Market Share Analysis
        14.1.1 Market Share by Region – Key Companies
        14.1.2 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Impetigo Therapeutic Market – Key Company List by Country Premium (Premium)
16. Impetigo Therapeutic Market - Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
* "Financials would be provided to private companies on best-efforts basis."
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.